Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

In addition, due to increased demand, many GLP-1 agonists are listed on the FDA's Drug Shortages list. People also must consider their comfort level regarding injections, which is the form of ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...